Iveric Bio to Present at the H.C. Wainwright Ophthalmology Virtual Conference
IVERIC bio (Nasdaq: ISEE) will feature President Pravin U. Dugel, M.D. at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. His presentation will be available on-demand from 7:00 a.m. ET, alongside a live panel discussion titled Addressing Unmet Medical Needs in Macular Degeneration at 11:00 a.m. ET. Investors can tune in via the Iveric Bio website, where an archived replay will be provided for 30 days post-conference. The company focuses on therapies for retinal diseases, including age-related and inherited conditions.
- None.
- None.
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17, 2021. This on-demand presentation will be available at 7:00 a.m. Eastern Time on August 17, 2021. Dr. Dugel will also participate in Addressing Unmet Medical Needs in Macular Degeneration – Dry AMD and Stargardt Disease, a one-time, live-only panel discussion, on August 17 at 11:00 a.m. Eastern Time.
Investors and the general public are invited to listen to both the on-demand and live webcasts on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com. An archived replay of the on-demand presentation will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.
About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. For more information on the Company, please visit www.ivericbio.com.
Forward-looking Statements
Any statements in this press release or made during the presentation referenced herein about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in the “Risk Factors” section of public filings made by Iveric Bio with the U.S. Securities and Exchange Commission. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release or the presentation, as applicable. Iveric Bio anticipates that subsequent events and developments may cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.
ISEE-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005016/en/
FAQ
What will Pravin U. Dugel discuss at the H.C. Wainwright Ophthalmology Virtual Conference related to ISEE?
When can investors watch the IVERIC bio presentation at the conference?
How can I access the archived replay of IVERIC bio’s conference presentation?
What is the focus of IVERIC bio's research and development?
What time is the live panel discussion about macular degeneration during the conference?
